(OM) Outset Medical - Ratings and Ratios

Outset Medical, Inc. (NASDAQ:OM) is a medical technology company specializing in the development of innovative hemodialysis systems. The companys flagship product, the Tablo Hemodialysis System, is a compact, all-in-one console designed for use in both acute care settings and home dialysis. Tablo integrates advanced features such as on-demand dialysate production, integrated water purification, and software-driven connectivity, making it a versatile solution for renal care.

Outset Medical manufactures and distributes the Tablo console, Tablo cartridges, and other consumables essential for the systems operation. Beyond the hardware, the company offers the Tablo Data Ecosystem, a suite of digital tools aimed at enhancing patient care and operational efficiency. This includes TabloHub, a customer-facing portal for healthcare providers; MyTablo, a patient-centric platform for remote monitoring; and TabloDash, an internal analytics platform for data-driven insights. These tools collectively support better outcomes, streamline workflows, and improve patient engagement.

Originally founded in 2003 under the name Home Dialysis Plus, Ltd., the company rebranded as Outset Medical, Inc. in January 2015. Headquartered in San Jose, California, Outset Medical has established itself as a pioneer in the hemodialysis industry, focusing on user-friendly, scalable, and cost-effective solutions for renal care. The companys mission is to expand access to dialysis, particularly in the home setting, while addressing the operational challenges faced by healthcare providers.

Based on the provided and , here is a 3-month forecast for Outset Medical, Inc. (NASDAQ:OM):

From a technical standpoint, the stock is currently trading at $0.63, below its SMA20 ($0.79) and SMA50 ($0.89), indicating near-term bearish momentum. However, the SMA200 of $1.66 suggests a potential oversold condition, which could trigger a rebound in the medium term. The ATR of $0.11 indicates relatively low volatility, suggesting that price movements may remain contained within a narrow range over the next quarter.

Fundamentally, the companys market cap of $34.01M reflects its smaller size relative to industry peers. The P/S ratio of 0.30 indicates undervaluation, which could attract value investors. However, the lack of positive P/E and forward P/E, along with the absence of RoE, raises concerns about profitability and earnings potential. The P/B ratio of 1.34 suggests that the stock is fairly valued relative to its book value, but investors should remain cautious given the companys financial performance trends.

Overall, the 3-month outlook for Outset Medical, Inc. is neutral to slightly bearish, with potential for a modest recovery if the company demonstrates progress in improving its financial health and expanding its market share in the hemodialysis sector.